Table 1 Proportion of patients carrying... | American Society of Hematology

Table 1

Proportion of patients carrying somatic mutations of SF3B1 in the study population

WHO category	No. of patients studied	No. of sequencing failures*	No. of evaluable patients	No. (%) of patients carrying SF3B1 mutations
MDS
RA	135	13	122	14 (11.5)
RARS	107	2	105	83 (79.0)
RCMD	102	6	96	6 (6.3)
RCMD-RS†	54	2	52	30 (57.7)
RAEB-1	87	4	83	7 (8.4)
RAEB-2	57	4	53	6 (11.3)
MDS del(5q)	22	0	22	4 (18.2)
MDS total	564	31	533	150 (28.1)
MDS/MPN
CMML	67	5	62	4 (6.5)
RARS-T	18	0	18	12 (66.7)
MDS/MPN, U	3	0	3	0
AML secondary to MDS	40	2	38	2 (5.3)
All patients studied	692	38	654	168 (25.7)

WHO category	No. of patients studied	No. of sequencing failures*	No. of evaluable patients	No. (%) of patients carrying SF3B1 mutations
MDS
RA	135	13	122	14 (11.5)
RARS	107	2	105	83 (79.0)
RCMD	102	6	96	6 (6.3)
RCMD-RS†	54	2	52	30 (57.7)
RAEB-1	87	4	83	7 (8.4)
RAEB-2	57	4	53	6 (11.3)
MDS del(5q)	22	0	22	4 (18.2)
MDS total	564	31	533	150 (28.1)
MDS/MPN
CMML	67	5	62	4 (6.5)
RARS-T	18	0	18	12 (66.7)
MDS/MPN, U	3	0	3	0
AML secondary to MDS	40	2	38	2 (5.3)
All patients studied	692	38	654	168 (25.7)

Failure was the result of insufficient sequence coverage.

†

RCMD-RS was a separate MDS category in the 2001 WHO classification of myeloid neoplasms²¹ but was incorporated into RCMD in the 2008 WHO classification.^2,3

View Large

This Feature Is Available To Subscribers Only